Slow Dose Escalation

The trial proceeds, but enrollment and dose escalation are deliberate because in vivo prime editing is new and regulators remain cautious. This path preserves long-term upside while delaying decisive clinical validation.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.